Eikon Therapeutics has raised another venture capital mega-round – bringing its total funding to date to $1.1bn – to build what it calls a “21st century biotechnology company.” The new financing will allow the Roger Perlmutter-helmed company to move its lead asset, EIK1001, into Phase III development.
Eikon Takes TLR7/8 Agonist Into Phase III With Latest VC Mega-Round
The company is moving its toll-like receptor 7/8 agonist into late-stage development for melanoma as it closes a $350.7m series D venture funding round.
More from Financing
• By
The four-year-old firm said it plans to advance programs toward the clinic from the funding round, which comes just over a year after signing two major pharma partnerships.
• By
Private Company Edition: The latest group of drug developers to announce venture capital financings is remarkable for its geographic diversity, from Character Biosciences’ $93m series B round in the US to Augustine’s $85m series B in Belgium to a $29.2m series C for Aculys in Japan.
• By
Kyoto-based venture moves HQ to California to expand R&D and business outreach for its regulatory T-cell technology, as it raises around $46m in public and private funding.
• By
The Belgian firm banks nearly €77.7m to push its Charcot-Marie-Tooth to proof-of-concept.
More from Therapy Areas
• By
The small interference RNA therapeutic can be used by patients regardless of inhibitor status.
• By
Merck expects Keytruda to come under Medicare price controls in 2028, but an analyst said the subcutaneous version could shield revenues for the franchise.
• By
The obesity market leader has unveiled its second deal in days, paying $75m upfront for a potential first-in-class ACSL5 inhibitor, while the deal also provides some respite for Lexicon.